EA201891491A1 - Полиморфные кристаллические формы обетихолевой кислоты - Google Patents

Полиморфные кристаллические формы обетихолевой кислоты

Info

Publication number
EA201891491A1
EA201891491A1 EA201891491A EA201891491A EA201891491A1 EA 201891491 A1 EA201891491 A1 EA 201891491A1 EA 201891491 A EA201891491 A EA 201891491A EA 201891491 A EA201891491 A EA 201891491A EA 201891491 A1 EA201891491 A1 EA 201891491A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mutual
cholic acid
crystal forms
acid
polymorphic crystal
Prior art date
Application number
EA201891491A
Other languages
English (en)
Russian (ru)
Inventor
Андре Штайнер
Хейди Венерлунд Поульсен
Эмили Жолибуа
Мелисса Револински
Ральф Гросс
Эмма Шарп
Фиона Дубас-Фишер
Алекс Иберлин
Original Assignee
Интерсепт Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55650649&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201891491(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US14/979,005 external-priority patent/US9982008B2/en
Application filed by Интерсепт Фармасьютикалз, Инк. filed Critical Интерсепт Фармасьютикалз, Инк.
Publication of EA201891491A1 publication Critical patent/EA201891491A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201891491A 2015-12-22 2016-01-08 Полиморфные кристаллические формы обетихолевой кислоты EA201891491A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/979,005 US9982008B2 (en) 2012-06-19 2015-12-22 Preparation and uses of obeticholic acid
PCT/US2016/012651 WO2017111979A1 (en) 2015-12-22 2016-01-08 Polymorphic crystalline forms of obeticholic acid

Publications (1)

Publication Number Publication Date
EA201891491A1 true EA201891491A1 (ru) 2018-11-30

Family

ID=55650649

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891491A EA201891491A1 (ru) 2015-12-22 2016-01-08 Полиморфные кристаллические формы обетихолевой кислоты

Country Status (15)

Country Link
EP (1) EP3394081A1 (ja)
JP (1) JP2018538331A (ja)
KR (1) KR20180095070A (ja)
CN (1) CN108495858A (ja)
AU (1) AU2016375566A1 (ja)
BR (1) BR112018012590A2 (ja)
CA (1) CA3009149A1 (ja)
CL (1) CL2018001720A1 (ja)
CO (1) CO2018006701A2 (ja)
EA (1) EA201891491A1 (ja)
IL (1) IL259998A (ja)
MX (1) MX2018007776A (ja)
PH (1) PH12018501318A1 (ja)
SG (1) SG11201805235XA (ja)
WO (1) WO2017111979A1 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105801653B (zh) * 2014-12-30 2018-04-17 苏州晶云药物科技有限公司 奥贝胆酸的晶型a及其制备方法
WO2018211413A1 (en) * 2017-05-15 2018-11-22 Dr. Reddy’S Laboratories Limited Solid forms of obeticholic acid and process for preparation
CN109280071A (zh) * 2017-07-19 2019-01-29 东莞东阳光药物研发有限公司 奥贝胆酸的晶型及其制备方法
CN107383139A (zh) * 2017-08-09 2017-11-24 杭州和泽医药科技有限公司 一种3α‑羟基‑7‑氧代‑5β‑胆烷酸新衍生物制备奥贝胆酸的方法
CZ31099U1 (cs) * 2017-09-05 2017-10-17 Zentiva, K.S. Krystalické formy (3a,5B,6a,7a)-6-ethyl-3,7- dihydroxycholan-24-ové kyseliny
CN109485687A (zh) * 2017-09-12 2019-03-19 成都弘达药业有限公司 奥贝胆酸的晶型j及其制备方法
WO2019106043A1 (en) 2017-11-29 2019-06-06 Hexal Ag Pharmaceutical composition comprising obeticholic acid
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
CN113264972B (zh) * 2020-02-14 2024-07-12 四川科伦药物研究院有限公司 一种制备奥贝胆酸的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20050912A1 (it) * 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
KR101881245B1 (ko) * 2012-06-19 2018-07-23 인터셉트 파마슈티컬즈, 인크. 오베티콜산의 제조법, 용도 및 고체 형태
CN106459136B (zh) * 2014-09-28 2018-06-26 江苏盛迪医药有限公司 一种奥贝胆酸的制备方法
JP6700274B2 (ja) * 2014-11-19 2020-05-27 エヌゼットピー ユーケー リミテッド ステロイドｆｘｒモジュレーター製造のための中間体としての６−アルキル−７−ヒドロキシ−４−エン−３−オンステロイド
TWI686401B (zh) * 2014-11-19 2020-03-01 英商Ｎｚｐ英國有限公司 化合物（三）
EA033603B1 (ru) * 2014-11-19 2019-11-08 Nzp Uk Ltd 6-альфа-алкил-6,7-дионовые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
CA2968301C (en) * 2014-11-19 2023-05-16 NZP UK Limited 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators

Also Published As

Publication number Publication date
EP3394081A1 (en) 2018-10-31
PH12018501318A1 (en) 2019-02-18
CO2018006701A2 (es) 2018-07-10
MX2018007776A (es) 2018-08-09
BR112018012590A2 (pt) 2018-12-04
KR20180095070A (ko) 2018-08-24
SG11201805235XA (en) 2018-07-30
CA3009149A1 (en) 2017-06-29
CL2018001720A1 (es) 2018-08-10
CN108495858A (zh) 2018-09-04
IL259998A (en) 2018-07-31
JP2018538331A (ja) 2018-12-27
AU2016375566A1 (en) 2018-07-05
WO2017111979A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
EA201891491A1 (ru) Полиморфные кристаллические формы обетихолевой кислоты
EA201590040A1 (ru) Получение, применение и твердые формы обетихолевой кислоты
EA201792354A1 (ru) Композиции обетихолевой кислоты и способы применения
EA201790384A1 (ru) Полиморфы селинексора
EA201800367A1 (ru) Способы лечения болезни хантингтона
EA201890908A1 (ru) Композиции и способы для лечения мышечной дистрофии дюшенна и сходных нарушений
IL264025A (en) Novel fatty acid-modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease
DK2887923T3 (da) Oftalmisk opløsning af polyoxyllipid eller polyoxylfedtsyre og behandling af øjentilstande
EA201890333A1 (ru) Противовирусные соединения
EA201892050A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
EA201171200A1 (ru) Полиморфы элтромбопага и солей элтромбопага, а также способы их получения
EA201990616A3 (ru) Дендримероподобные аминоамиды, обладающие активностью блокаторов натриевых каналов, для лечения сухости глаз и других заболеваний слизистых оболочек
EP3377116A4 (en) COMPOSITIONS AND METHODS FOR CORRECTING HEREDITARY OCULAR DISEASE
EP3174550A4 (en) Methods and compositions relating to treatment of pulmonary arterial hypertension
EA202091865A1 (ru) Композиции и способы для снижения экспрессии tau
EA201791807A1 (ru) Новый тритерпенон по с-3 с обратными амидными производными по с-17 в качестве ингибиторов вич
EA201890002A1 (ru) Положительные аллостерические модуляторы мускаринового рецептора м2
UA113627C2 (xx) Кристалічна форма циклоспорину a, фармацевтична композиція та спосіб лікування
EA201892514A1 (ru) Промежуточные соединения для синтеза производных желчных кислот, в частности обетихолевой кислоты
DK3713424T3 (da) Fremgangsmåde til behandling af hørfrø for at øge deres værdi som føde
EA201791945A1 (ru) Пирролидинкарбоксамидопроизводные и способы их получения и их применение
EA201600288A1 (ru) Замещенные фенилаланиновые производные
EA201790905A1 (ru) Способ лечения состояний, связанных с рецептором pgi2
DK3142655T3 (da) Sammensætninger og fremgangsmåder til behandling af hjertefibrose med ifetroban
EP3318261A4 (en) Use of zoledronic acid to prepare drug treating fatty liver disease